Significant improvement in all outcomes, including overall survival Wednesday, October 05, 2022 Updated 5-year results of the Unicancer PRODIGE-24 | CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for for patients with pancreatic cancer has been published in JAMA Oncology. Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P, Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial (ONLINE). JAMA Oncology 2022. https://doi.org/10.1001/jamaoncol.2022.3829 This practice-changing research confirmed the significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy regimen compared to the then standard treatment with gemcitabine. By five years after surgery, over one quarter of patients treated with mFOLFIRINOX were free of cancer compared to less than one out of five of those treated with gemcitabine. In addition, the survival of patients was significantly improved; almost half of patients who received mFOLFIRINOX were alive five years after the study versus less than one third who received gemcitabine.
